Yttrium
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Yttrium
- Molecular weight
- 88.91
- Structure (SMILES)
These details could not be displayed.
- mesh id d015019
- MeSH ID: D015019
- y
- Y
- YTTRIUM [HSDB]
- YTTRIUM [MI]
- Yttrium [WHO-DD]
- yttrium 89
- yttrium element
- Yttrium element
- yttrium hsdb
- yttrium mi
- yttrium who dd
- Yttrium-89
- CAS registry numbers
- 7440-65-5
- ChEMBL ID
- CHEMBL4650626
- InChIKey
- VWQVUPCCIRVNHF-UHFFFAOYSA-N
- PubChem compound IDs
- 23993
- RxNorm IDs (RxCUI)
- 1534770
- FDA ingredient codes (UNII)
- 58784XQC3Y
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- yttrium (90Y) clivatuzumab tetraxetan
- Type
- Antibody
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018364
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 1
- Molecular formula
- Y
- Monoisotopic mass
- 88.905838
- Natural product
- Yes
Related records
Trials (47)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
- A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
- Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
- Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
- Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
- Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine
- Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
- Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers
- Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
- Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers